1. HBW Insight

Sanofi Appealing Findings In Review Of Zantac 360 Doctor-Recommended Claims Challenged By J&J

Now Competing In Famotidine Category, Zantac 360 Used Doctors' Survey To Differentiate

 
• By Hannah Daniel

French pharma disagrees with NAD finding, following review of a claims made in online and social media ads, retailers' websites and a TV commercial, that the claim “#1 doctor recommended medicine” for Zantac 360 refers to the brand and not famotidine, also used in other OTC heartburn remedies, including Pepcid.

• Source: Shutterstock

Leaving ranitidine behind for famotidine as the active ingredient in its Zantac brand might leave Sanofi little room for differentiation in the OTC histamine-2 blockers space.

Sanofi isn't ready to accept the conclusion of BBB National Programs Inc

The French pharma disagrees with NAD attorney's finding, following a review of a claims made in online and social media ads, retailers' websites and a TV commercial, that the ad claim “#1 doctor recommended medicine” for Zantac 360 refers to the brand and

More from Ingredients & Safety

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By David Ridley

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.

Plenty For Industry To Do As EU Wastewater Directive Faces Legal Challenges

 
• By David Ridley

Engaging with EU member state legislators, stressing the impact of national EPR systems on the accessibility, availability, and affordability of medicines, reformulating products to reduce their financial contribution, and lobbying for expanding the scope of EPR schemes to include other polluting industries are all ways that the European consumer health industry can try and influence the way that the revised Urban Wastewater Treatment Directive is transposed into national legislation, law firm Mason Hayes & Curran explains.

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By David Ridley

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.

More from HBW Insight

US Consumer Health Executive News: CHPA Regulatory SVP, Kenvue CFO, PLT Sales Head

 
• By Malcolm Spicer

Former FDA OTC division director joins CHPA; PLT Health names global sales chief; and Kenvue loses CFO to Mattel, hires replacement from Kellanova.

C&D Taps Hand Sanitizer Category With Touchland

 
• By Malcolm Spicer

Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.

Beauty Firms Confused By State EPR Laws Have New Resource: EPR Academy

 
• By Eileen Francis

Beauty and personal care companies are struggling with compliance with state Extended Producer Responsibility laws, given the outstanding number of stakeholders that have still not registered products with Oregon’s EPR law, the first to go into effect.